PALO ALTO, Calif., May 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that two clinical abstracts have been accepted for presentation at the American Diabetes Association (ADA) 68th Scientific Sessions, which will be held in San Francisco, CA on June 6 - 10, 2008.
Ranexa(R) (ranolazine extended-release tablets)
Relationship Between Nonfasting Plasma Glucose Concentrations and Improved Glycemic Control in Patients with Diabetes and Coronary Artery Disease Treated with Ranolazine; Poster; Sunday, June 8, 2008, 12:00 - 2:00 p.m. and 6:15 - 7:30 p.m. PDT
Minority Angina Pectoris Patients at High Risk for Diabetes and Metabolic Syndrome; Poster; Sunday, June 8, 2008, 12:00 - 2:00 p.m. and 6:15 - 7:30 p.m. PDT
Additional information regarding the ADA 68th Scientific Sessions can be accessed at http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=58000.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved products include Ranexa(R) (ranolazine
extended-release tablets), indicated for the treatment of chronic angina in
patients who have not achieved an adequate response with other antianginal
drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic
stress agent in radionuclide myocardial perfusion imaging in patients
unable to undergo adequate exercise stress. CV Therapeuti
|SOURCE CV Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved